Table 5.
Patients with AE-ILD with 6-month follow-up data of pulmonary function test results
| Parameter | Mean (SD) | P-value (paired sample T-test) |
|---|---|---|
| VC% of pred. (n = 32a) | 0.158 | |
| AE-ILD | 66.2 (15.6) | |
| follow-up | 63.3 (17.4) | |
| FVC% of pred. (n = 38b) | 0.780 | |
| AE-ILD | 67.2 (16.9) | |
| follow-up | 66.6 (16.7) | |
| FEV1% of pred. (n = 38b) | 0.538 | |
| AE-ILD | 71.2 (16.5) | |
| follow-up | 70.0 (16.9) | |
| FEV1/FVC (n = 39c) | 0.069 | |
| AE-ILD | 84.9 (6.0) | |
| follow-up | 83.2 (5.8) | |
| DLCO% of pred. (n = 35d) | 0.912 | |
| AE-ILD | 41.9 (15.9) | |
| follow-up | 42.1 (15.4) |
a19 IPF, 13 other ILD
b21 IPF, 17 other ILD
c22 IPF, 17 other ILD
d18 IPF, 17 other ILD
Abbreviations: AE-ILD Acute exacerbation of interstitial lung disease, DLCO Diffusion capacity for carbon monoxide, FEV1 Forced expiratory volume in the first second, FVC Forced vital capacity, ILD Interstitial lung disease, IPF Idiopathic pulmonary fibrosis, SD Standard deviation, VC Vital capacity